Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
A phase 1, single-dose study of fresolimumab, an anti-TGF- antibody, in treatment-resistant primary focal segmental glomerulosclerosis
Expert-guided medical weight loss and wellness programs supporting real results and healthier, confident lives
Further advantageous effects are the improvement of lipid panel and blood pressure and the reduction of cardio-vascular (CV), renal, and liver damage [1]
Product-specific reports Primary Current batch report 99.41% HPLC purity Batch PP2601 Tested size 10mg Laboratory Research Use Only
Encapsulation Efficiency Analysis to confirm maximum glutathione protection
Always check for any changes in appearance before each use
US$ 20.76
US$ 28.11
US$ 27.87
US$ 28.91
US$ 27.73
US$ 23.66
